- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03287518
Evaluation of the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile
Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Benefit and Tolerability of WAK2017 on Endothelial Function, Blood Pressure and Lipid Profile
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The main objective of the study is to evaluate the endothelial function of WAK2017. In addition the effects on the blood pressure and the parameters of lipid metabolism will be explored.
Primary endpoint is defined as the difference in change in EndoPAT score RHI pre-dose and after 12 weeks of IP intake (visit V4 vs. V2) in comparison between the verum and placebo.
To characterize the benefit of the IP the following secondary endpoints will be analysed in comparison be-tween the verum and placebo:
- EndoPAT AI at V4 vs. V2
- SBP at V3, V4 vs. V2, respectively
- DBP at V3, V4 vs. V2, respectively
- Fasting LDL-C concentrations and non-HDL-C at V3, V4 vs. V2, respectively
- Fasting TC concentrations at V3, V4 vs. V2, respec-tively
- Fasting HDL-C concentrations at V3, V4 vs. V2, respectively
- Fasting TG concentrations at V3, V4 vs. V2, respectively
- Fasting LDL-C/HDL-C and TC/HDL-C ratio at V3, V4 vs. V2, respectively
- SCORE value at V3, V4 vs. V2, respectively
- Global evaluation of benefit by the subjects/ investigator at V4
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Maya Ulbricht
- Phone Number: 1 62 0049 3040 00 8
- Email: mulbricht@a-r.com
Study Contact Backup
- Name: Masaki Matsushita, PhD
- Phone Number: + 1 949 855 2776
- Email: mmatsushita@wakunaga.com
Study Locations
-
-
-
Berlin, Germany, 10369
- Recruiting
- analyze & realize GmbH
-
Contact:
- Ralf Uebelhack, MD
- Phone Number: 1 23 0049 3040 00 8
- Email: ruebelhack@analyze-realize.com
-
Contact:
- Udo Bongartz, MD
- Phone Number: 543 0049 3040 00 8
- Email: UBongartz@a-r.com
-
Sub-Investigator:
- Udo Bongartz, MD
-
-
Baden Würtemberg
-
Esslingen, Baden Würtemberg, Germany, 73728
- Not yet recruiting
- BioTeSys GmbH
-
Contact:
- Daniel Menzel, MD
- Phone Number: 36 0049 71135138
- Email: m.studie@biotesys.de
-
Contact:
- Jasmin Steudle
- Phone Number: 36 004971135138
- Email: m.studie@biotesys.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female subjects, 40-75 years
- BMI 25-34.9 kg/m2
- High normal or hypertension grade 1 blood pressure levels (130-159 / 85-99 mmHg) both at screening (mean of the 2nd and 3rd measurement during the assessment in triplicate at V1) and at baseline (mean of the 2nd and 3rd measurement during the assessment in triplicate at V2)
- EndoPAT score (RHI): < 2.2 at V1
Readiness to comply with study procedures, in particular:
- Consumption of the IP as instructed during the treatment period
- Adhering to former diet (except consumption of max. 2 garlic cloves per week) and physical activity
- Requirements for blood pressure / EndoPAT measurements
- Accepting blood draws
- Non-smoker / smoking cessation of last ≥12 months prior to V1
- Stable body weight in the last 3 months prior to V1 (<3 kg self-reported change)
- If allowed concomitant medications are taken this must have been stable at least during the last month prior to V1
Women of childbearing potential:
- Negative pregnancy testing (beta HCG-test in urine) at V1
- Commitment to use reliable contraception methods during the study Participation is based upon written informed consent by the participant following written and oral information by the investigator regarding nature, purpose, consequences and possible risks of the clinical study.
Exclusion Criteria:
- Known allergy or hypersensitivity to the components of the investigational product
- Known genetic hyperlipidemia
- Known secondary hypertension
- Known white-coat hypertension
- Known type-1-diabetes
- Uncontrolled or within the last 6 months prior to V1 diagnosed type-2-diabetes
- Untreated or non-stabilized thyroid disorder
History and/or presence of clinically significant cardiovascular disease as per investigator's judgement:
- Known congenital heart defects
- Myocardial infarction, heart failure, angina pectoris, life-threatening arrhythmia or stroke within the last 6 months prior to V1
- Existing thrombosis or disposition to thrombosis
Any other known significant or serious condition / disease that renders subjects ineligible, e.g.:
- History of malignancy within the past 5 years prior to V1
- Bleeding disorder and/or need for anticoagulants
- Current psychiatric care and/or use of neuroleptics
- Bariatric surgery in the last 12 months prior to V1
- Any known metabolic disease, gastrointestinal disorder or other clinically significant disease/disorder which in the investigator's opinion could interfere with the results of the study or the safety of the subject
- Known arm lymphedema (e.g. due to mastectomy)
Other deviation of laboratory parameter(s) at V1 that is:
- clinically significant or
- 2x ULN (upper limit of normal), unless the deviation is justified by a previously known not clinically relevant condition, e.g. Gilbert's syndrome)
Dietary habits that may interfere with the study objectives:
- Eating disorder
- Subjects with dietary restriction that may affect the study outcome
- Participation in a weight loss program
Use of following medication/supplementation within the last 4 weeks prior to V1 and during the study, according to investigator's jugdement:
- Drugs or supplements that can influence SBP or DBP (e.g. ACE inhibitors, diuretics, calcium channel or ß-blockers, grape seed extract, coenzyme Q10 etc.)
- Lipid lowering drugs (affecting lipid metabolism, platelet function or antioxidant status, etc.) or dietary or health supplements (e.g. omega-3 fatty acids, green tea extract, calcium, red yeast rice, phytosterols (incl. enriched products such as e.g. Becel), oat fiber, niacin, soy protein, psyllium seed husk, glucomannan, chitosan or probiotics/prebiotics)
- Drugs that can significantly influence cholesterol levels (e.g. corticosteroids, amiodarone, anabolic steroids)
- Medications (e.g. statins, renin angiotensin system inhibitors, nebivolol, carvedilol, calcium channel blockers) or supplements (e.g. cocoa) that can influence vascular endothelial function and/or blood flow within the last 4 weeks prior to V1 and during the study
- Antiplatelet agents and / or anticoagulants (e.g. warfarin, acetylsalicylic acid)
- Use of weight loss treatment
- Drug abuse
- Alcohol abuse (men: ≥21 units/week, women: ≥14 units/ week; 1 unit equals approximately 250 mL of beer, 100 mL of wine or 35 mL of spirits)
- Reported participation in night shift work 2 weeks prior to V1 and/or during the study
- Women of child-bearing potential: pregnant or breast-feeding
- Participation in another study or blood donation during the last 30 days prior to V1
- Any other reason deemed suitable for exclusion as per investigator's judgment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Verum
WAK2017 One (1) ml IP should be taken with breakfast and one (1) ml with supper every day.
|
WAK2017 is a solution with following active ingredients: Aged Garlic Extract.
One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
|
Placebo Comparator: Placebo
The placebo liquid is identical in colour and flavor to the verum. In order to maintain the blind with respect to the odour, the placebo will contain 3% Concentrated Aged Garlic Extract (DER 0.9-1.2:1), which is considered as inactive with respect to a potential beneficial effect. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day. |
One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Endo-PAT RHI value
Time Frame: Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
|
Change of EndoPAT score RHI measurement Visit 2 to Visit 4. EndoPAT parameter (Reactive Hyperemia Index (RHI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4
|
Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
EndoPAT Augmentation Index (AI)
Time Frame: Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
|
Change of EndoPAT parameter Augmentation Index (AI) will be assessed per Endo-PAT 2000 according to standardized procedures provided by the manufacturer (Itamar Medical Ltd., Israel), at Visit 2 and Visit 4
|
Visit 2 and Visit 4 after 84 days ± 6 days after Visit 2
|
Systolic Blood Pressure
Time Frame: 42 days ± 3
|
Change in Systolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3
|
42 days ± 3
|
Diastolic Blood Pressure
Time Frame: 42 days ± 3
|
Change in Diastolic Blood Pressure after 6 weeks ± 3 Visit 2 versus Visit 3
|
42 days ± 3
|
Systolic Blood Pressure
Time Frame: 84 weeks ± 6
|
Change in Systolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4
|
84 weeks ± 6
|
Diastolic Blood Pressure
Time Frame: 84 days ± 6
|
Change in Diastolic Blood Pressure after 12 weeks ± 6 Visit 2 versus Visit 4
|
84 days ± 6
|
Low Density Lipoprotein cholestorol (LDL-C)
Time Frame: 42 days ± 3
|
Change in LDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum LDL-C concentrations.
|
42 days ± 3
|
Low Density Lipoprotein cholestorol (LDL-C)
Time Frame: 84 days ± 6
|
Change in LDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum LDL-C concentrations.
|
84 days ± 6
|
non-High Density Lipoprotein cholestorol (non-HDL-C)
Time Frame: 42 days ± 3
|
Change in non-HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations.
The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol.
|
42 days ± 3
|
non-High Density Lipoprotein cholestorol (non-HDL-C)
Time Frame: 84 days ± 6
|
Change in non-HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum non-HDL-C concentrations.
The non-HDL cholesterol values are obtained by subtracting the HDL cholesterol value from the total cholesterol
|
84 days ± 6
|
Total Cholestorol (TC)
Time Frame: 42 days ± 3
|
Change in TC concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations.
|
42 days ± 3
|
Total Cholestorol (TC)
Time Frame: 84 days ± 6
|
Change in TC concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum Total Cholestorol (TC) concentrations.
|
84 days ± 6
|
High Density Lipoprotein cholestorol (HDL-C)
Time Frame: 42 days ± 3
|
Change in HDL-C concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum HDL-C concentrations.
|
42 days ± 3
|
High Density Lipoprotein cholestorol (HDL-C)
Time Frame: 84 days ± 6
|
Change in HDL-C concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum HDL-C concentrations.
|
84 days ± 6
|
Triglycerides (TG)
Time Frame: 42 days ± 3
|
Change in TG concentration after 6 weeks ± 3 Visit 2 versus Visit 3. Blood samples will be obtained for the assessment of serum TG concentrations.
|
42 days ± 3
|
Triglycerides (TG)
Time Frame: 84 days ± 6
|
Change in TG concentration after 12 weeks ± 6 Visit 2 versus Visit 4. Blood samples will be obtained for the assessment of serum TG concentrations.
|
84 days ± 6
|
LDL-C/HDL-C ratio
Time Frame: 42 days ± 3
|
Change in LDL-C/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3.
|
42 days ± 3
|
LDL-C/HDL-C ratio
Time Frame: 84 days ± 6
|
Change in LDL-C/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4.
|
84 days ± 6
|
TC/HDL-C ratio
Time Frame: 42 days ± 3
|
Change in TC/HDL-C ratio after 6 weeks ± 3 Visit 2 versus Visit 3.
|
42 days ± 3
|
TC/HDL-C ratio
Time Frame: 84 days ± 6
|
Change in TC/HDL-C ratio after 12 weeks ± 6 Visit 2 versus Visit 4.
|
84 days ± 6
|
SCORE Value
Time Frame: 42 days ± 3
|
The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment.
|
42 days ± 3
|
SCORE Value
Time Frame: 84 days ± 6
|
The SCORE value will be assessed on V2 - V4 using the European Low Risk Chart by the European Society of Cardiology (Perk et al., 2012), during biometric assess-ment.
|
84 days ± 6
|
Global Evaluation of benefit
Time Frame: 84 days ± 6
|
Both the subjects and investigator(s) will evaluate independently the benefit of the IP by means of a global scaled evaluation with "very good", "good", "moderate" and "poor".
|
84 days ± 6
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- WOA/002017
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Pressure
-
ROX Medical, Inc.CompletedHypertension | Blood Pressure, High | Blood Pressure, Resistant | Blood Pressure, UncontrolledUnited Kingdom, Netherlands, Belgium
-
SE HealthCentre for Aging and Brain Health InnovationCompletedHypertension | Blood Pressure | Hypotension | High Blood Pressure | Low Blood PressureCanada
-
DongGuk UniversityActive, not recruitingHypertension | Blood Pressure | Ambulatory Blood Pressure | Home Blood Pressure MeasurementKorea, Republic of
-
University of JordanCompletedBlood Pressure | Heart Rate | Airway PressureJordan
-
Istituto Auxologico ItalianoRecruitingArterial Hypertension | Ambulatory Blood Pressure Monitoring | Blood Pressure Determination | Home Blood Pressure MonitoringItaly
-
RadiRad Co., Ltd.Hualien Tzu Chi General HospitalNot yet recruitingBlood Pressure
-
Riphah International UniversityRecruiting
-
GE HealthcareNot yet recruiting
-
Guangdong Provincial People's HospitalRecruiting
-
Guangdong Provincial People's HospitalRecruiting